Pubblicazioni
|
PROFILO SCIENTIFICO Orcid Id: https://orcid.org/0000-0001-6133-0386 Scopus Author ID: 55531294800 Produzione scientifica e Indicatori Bibliometrici (calcolati al 15/06/2024) Numero totale di pubblicazioni su riviste internazionali con collegio di Referees riportate su Scopus e PubMed: 52 con - Numero totale di citazioni: 1152 (fonte Scopus) - Indice di Hirsch/H-index: 15 (fonte Scopus)
ELENCO COMPLETO DELLE PUBBLICAZIONI (TOT=181)
Contributi in Volume (capitolo o saggio):
1) Libanore M, Sighinolfi L, Segala D, Missere M.L, Rossi M.R. Infezione da HIV e intestino Patologie intestinali: dalla diagnosi alla terapia. Immagine Editore Firenze (2014). Capitolo 22: 211-215 HANDLE: 11392/2427729
Contributi in Rivista:
1) Cultrera R, Seraceni S, Segala D, Contini C. Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses. J Eukaryot Microbiol. 2001;Suppl:193S-194S. EID: 2-s2.0-0035544904
2) Cultrera R., Segala D., Seraceni S., Magno S.M., Contini C. Possibile implicazione di micoplasmi inusuali nelle infezioni respiratorie: applicazione di metodiche biomolecolari. It J Infect Dis 2001, 7: S134
3) Contini C., Cultrera R., Fainardi E., Seraceni S., Segala D., Misurati E., Castellazzi M., Granieri E. High rate of Chlamydia pneumoniae DNA detection in patients with multiple sclerosis. Presented at the 1st Dubrovnik International Conference on Multiple Sclerosis, Dubrovnik, Croatia, May 9-12, 2001. Neurologia Croatica 2001, 50(suppl 1). 35.
4) Contini C, Cultrera R, Seraceni S, Segala D, Romani R, Fainardi E, Cinque P, Lazzarin A, Delia S. The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS. J Med Microbiol. 2002 Oct;51(10): 879-90. DOI: 10.1099/0022-1317-51-10-879
5) Segala D., Grilli A., Cultrera R., Crapanzano VM., Biondin V., Contini C. Implicazioni diagnostiche e terapeutiche in un paziente con infezione da Parvovirus B-19 e sarcoidosi. It J Infect Dis 2005, 11: S67. HANDLE: 11392/1193068
6) Cultrera R., Segala D., Grilli A., Contini C. Riacutizzazione di epatite cronica HBV-relata dopo vaccinazione antinfluenzale. Descrizione di un caso clinico. It J infect dis. 2005; 11: S108. HANDLE: 11392/1193067
7) Bruschi F., Castagna B., Segala D., Contini C. Follow up sierologico di paziente affetto da recidiva di idatidosi epatica ed intolleranza all’albendazolo (ABZ) It J Infect Dis. 2005; 11: S75. HANDLE: 11392/525089
8) D., Grilli A., Cultrera R., Giuliodori M., Contini C. Risposta virologica sostenuta dopo trattamento breve con peginterferon alfa 2° e ribavirina in corso di epatite cronica da HCV. It J Infect Dis 2005; 11: S101. HANDLE: 11392/1193065 |
|
9) Crapanzano Minichello VM., Grilli A., Cultrera R., Segala D., Giuliodori M., Biondin V., Massari L., Contini C. Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati preliminari. It J infect Dis. 2005; 11: S63. HANDLE: 11392/1193064
10) Contini C, V.Crapanzano, V.biondin, R.Cultrera, D. Segala D. Recovery of Enterococcus gallinarum in patient with Infected cardiac pacemaker pockets International Journal of infectious Disease. 2006. HANDLE: 11392/524621
11) Vanessa Mary Crapanzano Minichello, Daniela Segala, Lorenzo Badia, Rosario Cultrera, Leo Massari, Carlo Contini Diagnostic and therapeutic aspects in patients with chronic osteomyelitis and prosthetic infections Microbiologia medica. 2008; 23: 29-34. DOI: 10.4081/mm.2008.2594
12) Baroncelli S, Pirillo MF, Galluzzo CM, Antoni AD, Ladisa N, Francisci D, d'Ettorre G, Segala D, Vivarelli A, Sozio F, Cirioni O, Weimer LE, Fragola V, Parruti G, Floridia M. Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. AIDS Res Hum Retroviruses. 2015 Jan;31(1):71-77. DOI: 10.1089/aid.2014.0060
13) Raffetti E, Donato F, Castelnuovo F, Ladisa N, Paraninfo G, Di Filippo E, Segala D, Cologni G, Bandera A, Zacchi F, Digiambenedetto S, Di Pietro M, Castelli F, Quiros-Roldan E; MASTER Cohort. The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study. J Transl Med. 2015 Mar 14;13:89. DOI: 10.1186/s12967-015-0446-8
14) Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E; MASTER Cohort. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health. 2015 Mar 12;15:235. DOI: 10.1186/s12889-015-1565-0
15) Guardigni V, Morieri ML, Segala D, Sighinolfi L. Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis. Curr HIV Res. 2016;14(4):346-53. DOI: 10.2174/1570162X14666160504101444
16) Massimo A, Teti E, Antinori A, Milazzoi L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, De Luca A, Cattelan A, Hasson H, Taliani G, Monforte AD, Mastroianni CM, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Bruno C, Giacometti A, Parruti G, Vullo V, Chirianni A, Pennica A, Pasquazzi C, Segala D, Sarmati L; SIMIT (Società Italiana di Malattie Infettivee Tropicali). Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clin Infect Dis. 2016 Dec 22. pii: ciw846. DOI: 10.1093/cid/ciw846
17) Taramasso L, Di Biagio A, Bovis F, Nicolini LA, Antinori A, Milazzo L, Sollima S, Gubertini G, Niero F, Saracino A, Bruno R, Borghi V, Montagnani F, Cattelan A, Hasson H, Taliani G, D'Arminio Monforte A, Mastroianni C, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Cacopardo B, Giacometti A, Parruti G, Vullo V, Chirianni A, Teti E, Pasquazzi C, Segala D, Andreoni M. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018 Feb 20;13(2):e0192627. DOI: 10.1371/journal.pone.0192627. eCollection 2018.
18) Ciancio G, Sighinolfi L, Furini F, Segala D, Farina I, Galuppi E, De Stefani E, Simone L, Boccia S, Grilli A, Pazzi P, Libanore M, Contini C, Govoni M. Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study. Clin Exp Rheumatol. 2018 Sep-Oct;36(5):862-870. WOS: 000445636700014
19) Mussini C, Roncaglia E, Borghi V, Rusconi S, Nozza S, Cattelan AM, Segala D, Bonfanti P, Di Biagio A, Barchi E, Focà E, Degli Antoni A, Bonora S, Francisci D, Limonta S, Antinori A, D'Ettorre G, Maggiolo F. A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). PLoS One. 2019 Sep 27;14(9):e0222650. DOI: 10.1371/journal.pone.0222650. ECollection 2019.
20) Libanore M, Segala D, Biagi E, Cultrera R, Sighinolfi L. COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy Journal of Medical case report. 2020 (2); 1-2
21) Cultrera R, Toselli R, Sarnicola C, Segala D, Mengoli A, Chiaretto G, Perri P, Sanguinetti R Identification and molecular characterization of Subramaniula asteroides causing human fungal keratitis: a case report BMC Infectious disease. 2021; 21:82. DOI:10.1186/s12879-021-05768-7)
22) Cultrera, R., Barozzi, A., Libanore, M., Mrangoni E., Pora R., Quarta B., Spadaro S., Ragazzi R., R., Marra A., Segala, D., Volta, C.A Co-infections in critically ill patients with or without covid-19: A comparison of clinical microbial culture findings International Journal of Environmental Research and Public Health. 2021, April: 18(8), 4358 DOI:10.3390/ijerph18084358
23) Pavasini, R., Fabbri, G., Marchini, F., Deserio M.A., Sanguettoli F., Verardi F.M.,Segala D., Pompei G., Tonet E., Serenelli M., Caglioni S, Guardigli G., Campo, G., Cultrera, R. Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome Journal of Clinical Medicine, 2022, Feb:11(3), 55. DOI:10.3390/jcm11030554
24) Borghi, A, Flacco ME, Pacetti L, Orioni G, Marzola E, Cultrera R, Guerra V, Manfredini R, Gaspari V, Segala D, Corazza M. Visits to Sexually Trasmitted Infection Clinics in Italy from January 2016 to November 2021: a multicenter, retrospective Study Journal of Personalized Medicine, 2023, 13(5) 731. DOI 10.3390/jpm13050731
|
|
Contributi in rivista come ICONA Foundation Study Group:
1) De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; ICoNA Foundation Study Group. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101. DOI: 10.1097/qai.0b013e318259875b
2) Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, Angarano G, Caramello P, Sighinolfi L, Mastroianni CM, Mazzarello G, Di Caro A, Di Giacomo C, d'Arminio Monforte A, Antinori A; ICONA Foundation Study Group. Am J Hematol. 2012 Aug;87(8):749-53. DOI: 10.1002/ajh.23236
3) Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study. AIDS. 2013 Mar 13;27(5):769-79. DOI: 10.1097/qad.0b013e32835cb747
4) d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort. Antivir Ther. 2014;19(3):319-24. DOI: 10.3851/imp2687
5) Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. J Antimicrob Chemother. 2014 Mar;69(3):735-41. DOI: 10.1093/jac/dkt426 |
|
6) Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; on behalf of the CHAIN Minority HIV-1 Variants Working Group. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2014 Oct 21. DOI: 10.1093/jac/dku426
7) Rozera G, Abbate I, Giombini E, Castagna A, De Luca A, Ceccherini-Silberstein F, Cozzi Lepri A, Cassola G, Torti C, d'Arminio Monforte A, Ippolito G, Capobianchi MR; ICONA Foundation Group. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. J Antimicrob Chemother. 2014 Nov;69(11):3085-94. DOI: 10.1093/jac/dku255
8) d'Arminio Monforte A, Galli L, Lo Caputo S, Lichtner M, Pinnetti C, Bobbio N, Francisci D, Costantini A, Cingolani A, Castelli F, Girardi E, Castagna A; ICONA Foundation Study Group. Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):258-67. DOI: 10.1097/qai.0000000000000297
9) Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study. Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. J Infect Dis. 2015 Jan 15;211(2):178-86. DOI: 10.1093/infdis/jiu417
10) Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar;2(3): 98-106. DOI: 10.1016/S2352-3018(15)00006-5
11) Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS One. 2015 May 1;10(5):e0124252. DOI: 10.1371/journal.pone.0124252
12) Cingolani A, Zona S, Girardi E, Cozzi-Lepri A, Monno L, Quiros Roldan E, Guaraldi G, Antinori A, D'Arminio Monforte A, Marcotullio S; Community-Oriented Study Group of the Icona Foundation Study Group. Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. HIV Med. 2015 Aug;16(7):412-20. DOI: 10.1111/hiv.12226. Epub 2015 May 11.
13) Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS One. 2015 Dec 7;10(12). DOI: 10.1371/journal.pone.0140877
14) Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, Rusconi S, Caramello P, Abrescia N, Mussini C, Monno L, d'Arminio Monforte A; ICONA Foundation Study Group. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clin Microbiol Infect. 2016 Mar;22(3):288.e1-8. DOI: 10.1016/j.cmi.2015.10.026
15) Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group.. Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. DOI: 10.1097/QAI.0000000000000849
16) d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, Rizzardini G, Manconi PE, Gianotti N, Quirino T, Pinnetti C, Rusconi S, De Luca A1, Antinori A; Icona Foundation Study cohort. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS One. 2016 Jun 27;11(6):e0156360. DOI: 10.1371/journal.pone.0156360 |
|
17) Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. J Antimicrob Chemother. 2016 Sep;71(9):2663-9. DOI: 10.1093/jac/dkw185
18) Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Galli M, Di Perri G, Viale P, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS One. 2016 Oct 7;11(10):e0160761. DOI: 10.1371/journal.pone.0160761
19) Nicola Gianotti , Alessandro Cozzi-Lepri, Andrea Antinori, Antonella Castagna, Andrea De Luca, Benedetto Maurizio Celesia, Massimo Galli, Cristina Mussini, Carmela Pinnetti, Vincenzo Spagnuolo, Antonella d’Arminio Monforte, Francesca Ceccherini-Silberstein, Massimo Andreoni, On behalf of Icona Foundation Study and mono-PI/r database Study Cohorts Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients PLOS ONE.- ISSN 1932-6203. - 12:2(2017), pp. e0171611-e0171611. DOI:10.1371/journal.pone.0171611
20) Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. DOI: 10.1016/j.cmi.2016.12.003
21) Antonella d'Arminio Monforte, Alessandro Cozzi-Lepri2, Francesca Ceccherini-Silberstein, Andrea De Luca4, Sergio Lo Caputo5, Antonella Castagna6, Cristina Mussini7, Antonella Cingolani, Alessandro Tavelli9, Milensu Shanyinde, Andrea Gori, Enrico Girardi, Massimo Andreoni, Andrea Antinori, Massimo Puoti, on behalf of Icona Foundation and HepaIcona Study Group Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort PLOS ONE.-ISSN 1932-6203.-12:5(2017), pp. e0177402-e0177402. DOI:10.1371/journal.pone.0177402
22) Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL Infection. 2017 Aug;45(4):521-528. DOI: 10.1007/s15010-017-1018-z
23) De Luca A, Lorenzini P, Castagna A, Puoti M, Gianotti N, Castelli F, Mastroianni C, Maggiolo F, Antinori A, Guaraldi G, Lichtner M, dʼArminio Monforte A; ICONA Foundation Study. Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):465-471. DOI: 10.1097/QAI.0000000000001443
24) Gianotti N, Marchetti G, Antinori A, Saracino A, Gori A, Rizzardini G, Lichtner M, Bandera A, Mussini C, Girardi E, dʼArminio Monforte A, Cozzi-Lepri A. Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):417-422. DOI: 10.1097/QAI.0000000000001522
25) A Saracino, A Cozzi-Lepri, M Shanyinde, F Ceccherini Silberstein, S Nozza, A Di Biagio, G Cassola, G Bruno, M Capobianchi, M Puoti, L Monno, A d'Arminio Monforte; ICONA Foundation Study. HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients PLoS One. 2018 Jan 11;13(1):e0190302. DOI: 10.1371/journal.pone.0190302. eCollection 2018.
26) A d'Arminio Monforte, P Lorenzini, A Cozzi-Lepri3, C Mussini, A Castagna5, F Baldelli, M Puoti, F Vichi, A Maddaloni, S Lo Caputo, Nicola Gianotti, A Antinori on behalf of the Icona Foundation Study Group. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 Apr;19(2):52-60. DOI: 10.1080/15284336.2018.1440691. Epub 2018 Mar 1
27) Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison HIV Med. 2018 May 30: 1-10. DOI: 10.1111/hiv.12628
28) Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study BMC Med. 2018 May 29;16(1):79. DOI: 10.1186/s12916-018-1046-2.
29) Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, Gori A, Girardi E, Mussini C, Bonfanti P, Ammassari A, d'Arminio Monforte A; Icona Foundation Study Group. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. BMC Public Health. 2018 Jul 13;18(1):870. DOI: 10.1186/s12889-018-5804-z.
30)Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. DOI: 10.1093/jac/dky350.
31) Chiara Dentone, Antonio Di Biagio, Alessandro Cozzi Lepri, Daniela Fenoglio, Gilberto Filaci, Miriam Lichtner, Stefania Carrara, Andrea Giacometti, Laura Sighinolfi, Giulia Marchetti, Andrea Antinori, Antonella D’arminio Monforte & for the ICONA Foundation Study Group Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients HIV Clin Trials. 2018 Aug;19(4):158-162. DOI: 10.1080/15284336.2018.1488453
32) Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019 Jan;22(1):e25227. DOI: 10.1002/jia2.25227.
33) d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, Castagna A, Girardi E, Antinori A, Lo Caputo S, Guaraldi G, Cozzi-Lepri A; ICONA Foundation Study Group. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. HIV Med. 2019 Feb;20(2):99-109. doi: 10.1111/hiv.12683. Epub 2018 Nov 21.
34) D Armenia, D Di Carlo, A Cozzi-Lepri, A Calcagno, V Borghi, C Gori, A Bertoli, W Gennari, R Bellagamba, A Castagna, A Latini, C Pinnetti, S Cicalini, A Saracino, G Lapadula, S Rusconi, F Castelli, S Di Giambenedetto, M Andreoni, G Di Perri, A Antinori, C Mussini, F Ceccherini-Silberstein, A d’Arminio Monforte, CF Perno, MM Santoro; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. Antivir Ther. 2019 Apr 12. DOI: 10.3851/IMP3309.
35) Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group . Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. DOI: 10.1093/jac/dkz237.
36) Leone S, Lorenzini P, Cozzi-Lepri A, Orofino G, Bernacchia D, Castagna A, Menozzi , Guaraldi G, Madeddu G, Di Biagio A, Puoti M, Gori, A. d'Arminio Monforte A; ICONA Foundation Study Group. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study Eur J Clin Microbiol Infect Dis 2019 Oct;38(10):1857-1865. DOI: 10.1007/s10096-019-03618-8
37) Shanyinde M, Girardi E, Puoti M, De Luca A, Sighinolfi L, Caterina UF, Caramello P, Lampe FC, D'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? BMC Public Health. 2019 Oct 15;19(1):1291. DOI: 10.1186/s12889-019-7608-1.
38) Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A; ICONA Foundation Study Group . Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019 Nov 1;74(11):3295-3304. DOI: 10.1093/jac/dkz353.
39) d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group . Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. DOI: 10.1093/jac/dkz512.
40) Lavinia Fabeni, Maria Mercedes Santoro 2, Patrizia Lorenzini, Stefano Rusconi, Nicola Gianotti, Andrea Costantini, Loredana Sarmati, Andrea Antinori, Francesca Ceccherini-Silberstein, Antonella d’Arminio Monforte, Annalisa Saracino, Enrico Girardi and on behalf of the Icona Foundation Study Cohort Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy Viruses 2020, 12, 791; DOI:10.3390/v12080791
41) A Vergori, R Gagliardini, N Gianotti, A Gori, M Lichtner, A Saracino, A De Vito, A Cascio, A Di Biagio, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri on behalf of the ICONA Foundation Study Network Int J Antimicrob Agents. 2020 Sep 9:106154. DOI: 10.1016/j.ijantimicag.2020.106154
42) Vourli, G., Noori, T., Pharris, A., ... Segala D., … Norgren, H., Wendahl, S. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? Clinical Infectious Diseasesthis. 2020, 71(11), pp. 2905–2916. DOI:10.1093/cid/ciaa696
43) Vincenzo Malagnino, Carlotta Cerva, Antonella Cingolani, Francesca Ceccherini-Silberstein, Alessandra Vergori, Gianluca Cuomo, Carlo Federico Perno, Massimo Puoti, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri, Massimo Andreoni, and Loredana Sarmati for the ICONA Foundation Study Group HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients Open Forum Infectious Diseases. 2021 Jan Vol 8, Iss 1:ofaa566. DOI:10.1093/ofid/ofaa566
44) Bandera, A., Lorenzini, P., Taramasso, L.,… Segala D.,...Starnini, G., Ialungo, A. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort Journal of Viral Hepatitis,2021, 28(5), pp. 779–786. DOI:10.1111/jvh.13488
45) Chammartin, F., Lodi, S., Logan, R., … Segala D.,...Wandeler, G., Yerly, S. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study Annals of Internal Medicine, 2021, 174(6), pp. 768–776. DOI:10.7326/M20-5226
46) D'arminio Monforte A, Tavelli A, Sala M, Mondi A, Rusconi S, Antinori S, Puoti M, Celesia BM, Taramasso L, Saracino A, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Group. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. J Antimicrob Chemother. 2023 Apr 3;78(4):933-945. doi: 10.1093/jac/dkad026. PMID: 36775983
47) d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. PMID: 37649460
48) d'Arminio Monforte A, Tavelli A, Salpini R, Piermatteo L, D'Anna S, Carrara S, Malagnino V, Mazzotta V, Brancaccio G, Marchetti GC, Rosselli Del Turco E, Rossotti R, Mussini C, Antinori A, Lo Caputo S, Ceccherini Silberstein F, Gaeta GB, Svicher V, Puoti M; Icona Foundation Study Group. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort. Liver Int. 2024 Feb;44(2):603-613. doi: 10.1111/liv.15804. Epub 2023 Dec 15. PMID: 38100128
49) d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort. J Antimicrob Chemother. 2024 Jun 3;79(6):1279-1288. doi: 10.1093/jac/dkae081. PMID: 38581349
Contributi in rivista come D:A:D Study Group:
1) Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013 May 1;207(9):1359-69. DOI: 10.1093/infdis/jit043
2) Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. MC Infect Dis. 2013 Oct 9;13:471. DOI: 10.1186/1471-2334-13-471
3) Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013 Nov 13;27(17):2735-48.DOI: 10.1097/01.aids.0000432457.91228.f3
4) Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol. 2014 Mar 25;15:51. DOI: 10.1186/1471-2369-15-51
5) Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med. 2014 Nov;15(10):595-603. DOI: 10.1111/hiv.12162
6) Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3). DOI: 10.1371/journal.pmed.1001809
7) Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. DOI: 10.1097/qai.0000000000000523
8) Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D Study Group). Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016 Jan;3(1):e23-32. DOI: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.
9) Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016 Apr;17(4):255-68. DOI: 10.1111/hiv.12294
|
|
10) Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study J Int AIDS Soc. 2018 Mar;21(3). DOI: 10.1002/jia2.25083
11) Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. PMID: 38663013
Contributi in rivista come NIA Study Group
1) Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother. 2010 May;44(5):838-43. DOI: 10.1345/aph.1m688
2) Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS. 2012 Jul;23(7):459-63. DOI: 10.1258/ijsa.2012.011391
3) Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. J Antimicrob Chemother. 2013 Jan;68(1):193-9. DOI: 10.1093/jac/dks341
Contributi in rivista come PITER Study Group
1) Loreta Kondili1, Loredana Falzano2, Alessandra Mallano2, Maria Giovanna Quaranta2, Marco Mirra,Liliana Elena Weimer, Luca Fucili, Massimiliano Di Gregorio, Stefano Lucattini, Maurizio Massella,Roberta Terlizzi, Erika Olivieri, Federica Magnani, Alessandra Mattei, Stefano Rosato3,Maria Elena Tosti, Stefano Vella e il Gruppo Collaborativo PITER La piattaforma per lo studio delle terapia delle epatiti virali (PITER): il primo grande studio nazionale sull'infezione cronica da virus dell'epatite C Notiziaro dell’ISS. 2015 Maggio (28); 3-10.
2) LA Kondili, S Vella and PITER Collaborating Group.
3) LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, AL Zignego, A Ciancio, A Di Leo, G Raimondo, C Ferrari, G Taliani, G Borgia, TA Santantonio, P Blanc, GB Gaeta, A Gasbarrini, L Chessa, EM Erne, E Villa, D Ieluzzi, FP Russo, P Andreone, M Vinci, C Coppola, L Chemello, S Madonia, G Verucchi, M Persico, M Zuin, M Puoti, A Alberti, G Nardone, M Massari, G Montalto, G Foti, MG Rumi, MG Quaranta, A Cicchetti, A Craxì, S Vella on behalf of PITER Collaborating Group.
4) LA Kondili, S Vella, AL Zignego, PITER collaborating Group. Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice. Liver International. 2018;38:183. DOI: 10.1111/liv.13490
5)Gruppo Collaborativo della Piattaforma Italiana per lo Studio della Terapia delle Epatiti Virali (PITER) e Alta Scuola di Economia e Management dei Sistemi Sanitari (ALTEMS) L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Notiziario dell'Istituto Superiore di Sanità. 31(1):3-7; 2018. HANDLE:11392/2417804
6) LA Kondili, S Robbins, S Blach, I Gamkrelidze, AL Zignego, MR Brunetto, G Raimondo, G Taliani, A Iannone, FP Russo, TA Santantonio, M Zuin, L Chessa, P Blanc, M Puoti, M Vinci, EM Erne, M Strazzabosco, M Massari, P Lampertico, MG Rumi, A Federico, A Orlandini, A Ciancio, G Borgia, P Andreone, N Caporaso, M Persico, D Ieluzzi, S Madonia, A Gori, A Gasbarrini, C Coppola, G Brancaccio, A Andriulli, MG Quaranta, S Montilla, H Razavi, M Melazzini, S Vella, A Craxì, PITER collaborating group. Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? Liver International. 2018;38:2190-2198. DOI: 10.1111/liv.13901
7) Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at http://www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics. 2019 Feb;37(2):255-266. DOI: 10.1007/s40273-018-0733-3.
8) Kondili LA, Gamkrelidze, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int 2020 Feb 20. DOI: 10.1111/liv.14408.
9) Quaranta MG, Rosato S, Ferrigno L, Amoruso DC, Monti M, Di Stefano P, Filomia R, Biliotti E, Migliorino G, Russo FP, Degasperi E, Chemello L, Brancaccio G, Blanc P, Cannizzaro M, Barbaro F, Morsica G, Licata A, Kondili LA; PITER collaborating group. Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. Antivir Ther. 2020 Apr 3. DOI: 10.3851/IMP3350.
10) Quaranta MG, Ferrigno L, Monti M, Filomia R, Biliotti E, Iannone A, Migliorino G, Coco B, Morisco F, Vinci M, D'Ambrosio R, Chemello L, Massari M, Ieluzzi D, Russo FP, Blanc P, Verucchi G, Puoti M, Rumi MG, Barbaro F, Santantonio TA, Federico A, Chessa L, Gentile, Zuin M, Parruti G, Morsica G, Kondili LA; PITER Collaborating Group. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatol Int. 2020 Apr 11. DOI: 10.1007/s12072-020-10034-0.
Contributi in rivista frutto di altre collaborazioni:
1) Ensoli, B; Bellino, S; Tripiciano, A; Longo, O; Francavilla, V; Marcotullio, S; Cafaro, A; Picconi, O; Paniccia, G; Scoglio, A; Arancio, A; Ariola, C; Ruiz Alvarez, Mj; Campagna, M; Scaramuzzi, D; Iori, C; Esposito, R; Mussini, Cristina; Ghinelli, F; Sighinolfi, L; Palamara, G; Latini, A; Angarano, G; Ladisa, N; Soscia, F; Mercurio, Vs; Lazzarin, A; Tambussi, G; Visintini, R; Mazzotta, F; Di Pietro, M; Galli, M; Rusconi, S; Carosi, G; Torti, C; Di Perri, G; Bonora, S; Ensoli, F; Garaci, E. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. Plos one,11 Nov 2010, 5(11):e13540. DOI: 10.1371/journal.pone.0013540
2) ,May MT Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012 Dec;41(6):1807-20. DOI: 10.1093/ije/dys164
3) Efsen AM, Panteleev AM, Grint D, Podlekareva DN, Vassilenko A, Rakhmanova A, Zeltina I, Losso MH, Miller RF, Girardi E, Caylá J, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Lundgren JD, Mocroft A, Kirk O; HIV/TB Study Group. TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. Biomed Res Int. 2013;2013:373601. DOI: 10.1155/2013/373601
4) F. Marando, G. Gualberti, A.M. Costanzo, U. di Luzio Paparatti, M. Franzetti, A. Ammassari, A. Antinori & M. Galli Discrepancies between physician's perception of depression in HIV patients and self-reported CES D-20 assessment: the DHIVA study AIDS care. 2016; 28:2, 147-159. DOI: 10.1080/09540121.2015.1080794
5) Capone S, et al GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-COV-2 in randomized placebo-controlled phase 2 trial Cell Reports Medicine, 2023, 4(6), 101084. DOI 10.1016/j.xcrm.2023.101084
|
|
Contributi in Atto di convegno (Poster/Abstract):
1) Contini C., Cultrera R., Fainardi E., Seraceni S., Segala D., Misurati E., Castellazzi M., Granieri E. High rate of Chlamydia pneumoniae DNA detection in patients with multiple sclerosis. Presented at the 1st Dubrovnik International Conference on Multiple Sclerosis, Dubrovnik, Croatia, May 9-12, 2001. Neurologia Croatica 2001, 50(suppl 1). 35.
2) Cultrera R, Germani R, Pelti M, Segala D, Misurati E, Contini C. Ureaplasma urealyticum in preterm infants with respiratory distress syndrome. The main responsible or a cofactor? Abstract Book of the 14th International IOM Congress, Vienna, July 2002: 119.
3) Cultrera R., Misurati E., Segala D., Seraceni S., Romani R., Angelici E., Germani R., Pelti M., Contini C. Evidence of Ureaplasma urealyticum and Pneumocystis carinii in very low birth weight infants with respiratory distress syndrome (RDS). A synergistic role? European Respiratory Society (ERS) September 14-18 2002.
4) Contini C., Cultrera R., Buonfante D., Seraceni S., Segala D., Pignata D., Quattrucci P., Angelici E. Does C. pneumoniae and P. carinii infections have a different role in patients with cystic fibrosis and lung transplantation? European Respiratory Society (ERS) September 14-18 2002.
5) Contini C, Seraceni S, Giuliodori M, Segala D, Cultrera R, Granirei E. Infezione del sistema nervoso centrale da chlamydia pneumonaie. Possibile ruolo etiopatogenetico nella sclerosi multipla. Microbiologia Medica, 2005; 20: 141. DOI: 10.4081/mm.2005.3463
6) C.Contini, S.seraceni, M.Giuliodori, D.Segala, R.Cultrera, M.Govoni, F.Trotta. Investigation of Chlamydia pneumonite and mycoplasma Spp in clinical specimens from patients with arthritis. Clin Microbiol Infect 2005; 11: 179-180. HANDLE: 11392/520229
7) Segala D., Crapanzano Minichello V.M., Grilli A., Cultrera R., Contini C. Epatite cronica C e syndrome di Ehlers Danlos (EDS). Un caso clinico 6°Simit, congresso nazionale 2007. HANDLE: 11392/525110
8) V.M. Crapanzano Minichello; L. Badia; A. Grilli; D. Segala; S. Seraceni; S. Scivales; R.Cultrera; C. Contini Indagine retrospettiva delle linfoadenopatie infettive. ruolo dei tests molecolari. 6°Simit, congresso nazionale 2007. HANDLE: 11392/525429
9) R. Cultrera; G. Zuliani; D. Segala; S. Seraceni; R. Fellin; C. Contini Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 6°Simit, congresso nazionale 2007. HANDLE: 11392/525438
10) Contini C, Segala D, Cultrera R, Crapanzano Minichello VM. Detection of Parvovirus B19 and Chlamydophila pneumoniae in a Patient with Atypical Sarcoidosis. Infection. 2007 Sep 28; DOI: 10.1007/s15010-007-6313-7
11) Bucciardini, R; Floridia, M; Weimer, LE; Fragola, V; Massella, M; Baroncelli, S; Pirillo, MF; Galluzzo, CM; Donnini, S; Mirra, M; Di Gregorio, M; Lucattini, S; Fucili, L; Baldelli, F; Francisci, D; Martinelli, L; Bastianelli, S; Pastore, G; Ladisa, N; Volpe, A; Vullo, V; D'Ettore, G; Ceccarelli, G; Andreoni, M; Sarmati, L; Delle Rose, D; Montano, M; Tozzi, V; Libertone, R; Pucillo, L; Narciso, P; Bellagamba, R; Tommasi, C; Petrosillo, N; Cicalini, S; Sighinolfi, L; Segala, D; Armignacco, O; Preziosi, R; Ferrari, C; Antoni, AD; Cavalli, A; Parruti, G; Sozio, F; Cosentino, L; Dionisio, D; Vivarelli, A; Manconi, PE; Ortu, F; Di Martino, ML; Chiodo, F; Biagelti, C; Borderi, M; Boni, P; Del Gobbo, R; Paggi, AM; Silvestri, C; Scalise, G; Giacometti, A; Cirioni, O; Mura, MS; Mannazzu, M; Coinu, G; Bellissima, P; Bonfante, S; Neri, D; Guaraldi, G; Beghetto, B ISS-NIA Italian cohort: new anti-HIV inhinitors in patients experienced to IP, NRTI, NNRTI. Infection 2009; 37 (Suppl.II):63. HANDLE: 11392/2417776
12) D.Segala, R.Roda, C.Mussini, M.Meschiari, A.Cattelan, L.Sasset, L.Sighinolfi. Raltegravir plus a boosted protease inhibitor: experience in patients with resistance and/or NRTI-related adverse events Infection 2010; 38:59. DOI: 10.1007/s15010-010-1001-4
13) D.Segala, R.Roda, M.Libanore, L.Sighinolfi. Long-term safety of dual regimen of raltegravir and ritonavir-boosted protease inhibitor in ARV-experienced patients with chronic kidney disease Infection 2011; 39:76. HANDLE: 11392/2417921
14) Weimer, Le; Floridia, M.; Bucciardini, R.; Baroncelli, S.; Galluzzo, C. M.; Pirillo, M. F.; Fragola, V.; Donnini, S.; Mirra, M.; di Gregorio, M.; Lucattini, S.; Fucili, L.; Angarano, G.; Ladisa, N.; Volpe, A.; Vullo, V.; D'Ettorre, G.; Ceccarelli, G.; Andreoni, M.; Sarmati, L.; Delle Rose, D.; Tozzi, V.; Petrosillo, N.; Bellagamba, R.; Libertone, R.; Cicalini, S.; Sighinolfi, L.; Segala, D.; Armignacco, O.; Preziosi, R.; Ferrari, C.; Degli Antoni, A.; Cavalli, A.; Parruti, G.; Sozio, F.; Cosentino, L.; Vivarelli, A.; Manconi, P. E.; Ort, F.; Di Martino, M. L.; Viale, P.; Verrucchi, G.; Tedeschi, S.; Mura, M. S.; Mannazzu, M.; Cattari, G.; Tavio, M.; del Gobbo, R.; Mataloni Paggi, A.; Giacometti, A.; Cirioni, O.; Marchionni, E.; Silvestri, C.; Sebastianelli, S.; Brescini, L.; Baldelli, F.; Giovanni, Guaraldi; Nardini, Giulia; Chiara, Stentarelli; Barbara, Beghetto Limited occurence od 3-4 new grade toxicity events with salvage regimens based on raltegravir and/or maraviroc: 96 weeks Data from the ISS NIA cohort study New microbiologica, vol 36, suppl 1-2013. HANDLE: 11392/2417780
15) L.Sighinolfi, D.Segala, R.Roda, M.Libanore, F.Ghinelli Polmonite in corso di infezione da virus influenzale A (H1N1) in paziente HIV 8°Simit, congresso nazionale 2009
16) D.Segala, L.Sighinolfi, R.Roda, F.Ghinelli Popolazione sieropositiva di età > 60 anni:caratteristiche di una realtà emergente 9°Simit, congresso nazionale 2010
17) L.Sighinolfi, D.Segala, R.roda, F.Ghinelli Personalizzazione dei percorsi di cura dei pazienti in HAART stabile ed efficace:è possibile semplificare il follow up? 9°Simit, congresso nazionale 2010
18) M.Libanore, L.Sighinolfi, R.Roda, D.Segala, M.Pantaleoni, E.Misurati, S.Carradori, M.R.Rossi. Tasso di mortalità della polmonite batterica nel paziente con infezione da HIV 9°Simit, congresso nazionale 2010
19) M.Libanore, G.Guerra, V.Sambri, R.Bicocchi, E.Misurati, M.Pantaleoni, S.Carradori, R.Roda, D.Segala, L.Sighinolfi. Assetto linfocitario nell’infezione neuroinvasiva da West Nile virus:dati preliminari 9°Simit, congresso nazionale 2010
20) M.Libanore, R.Bicocchi, V.SambriE.Misurati, M.Pantaleoni, S.Carradori, E.Misurati, D.Segala, R.Roda, L.Sighinolfi. Insufficienza respiratoria acuta ad esito infausto da virus A H1N1 in paziente con infezione da HIV 9°Simit, congresso nazionale 2010
21) L.E. Weimer… L.sighinolfi, D.Segala, …, L.Fucili. Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 6th IAS Conference on HIV pathogenesis, treatment and prevention
22) Segala D.,Roda R., Fucili A., Sighinolfi L. Applicazione dello score di Framingham nella pratica clinica routinaria: risultati preliminari 10° congresso nazionale SIMIT (2011)
23) Segala D., Battagin G., Ciccone M., Roda R., Libanore M., Sighinolfi. Leishmaniosi viscerale in paziente HIV: diffusione dell’infezione in zona non endemica. 10° congresso nazionale SIMIT (2011) 24) Segala D., Missere ML., Roda R., Bianchi S., Scanavacca P., Sighinolfi L. Infectious diseases specialist and pharmacist collaboration in HIV outpatients care: preliminary results 4° congresso ICAR (2012)
25) Segala D., Missere ML., Roda R., Bianchi S., Scanavacca P., Sighinolfi L. Integrazione fra infettivologo e farmacista nella gestione del paziente HIV positivo in terapia. 11° congresso nazionale SIMIT (2012). HANDLE: 11392/2418000
26) Missere M.L., Segala D*., Bianchi S., Carletti R., Scanavacca P., Sighinolfi L*., Roda R*. Ruolo del farmacista clinico nella gestione farmacologia del paziente HIV: appropriatezza della terapia e monitoraggio dell’aderenza. XXXIII National Conference SIFO (Società Italiana di Farmacia Ospedaliera) (2012)
27) Missere M.L., Segala D*., Bianchi S., Carletti R., Scanavacca P., Sighinolfi L*. Profilo prescrittivo e risultati terapeutici della terapia antiretrovirale nel paziente HIV presso l’Azienda Ospedaliero Universitaria di Ferrara. XXI National Conference "La valutazione dell'uso e della sicurezza dei farmaci: esperienze in Italia" ISS (2012)
28) Castagna A., Galli L., Bigoloni A., Carini E., Segala D., Antinori A., Molteni C., Cossarini F., Nozza S.,Spagnolo V., Gianotti N., Lazzaroni A. Impact of Lamivudine Monotherapy in failing patients with multidrug-resistant HIV: final 48 weeks results ( MONO - AIFA FARM7PAZS3) 11° International congress on drug therapy in HIV infection (2012)
29) Weimer L.E. for the ISS-NIA Study Group Response to raltegravir-based salvage therapy in HIV-infected patients with HCV or HBV coinfection 4° congresso ICAR (2012)
30) Segala D., Missere M.L., Bianchi S., Scanavacca P., Libanore M., Sighinolfi L. La applicazione delle Linee Guida Italiane di terapia antiretrovirale nella realtà ambulatoriale: efficacia e tollerabilità della cART di prima linea. 12° congresso nazionale SIMIT (2013). HANDLE: 11392/2418005
31) P.Nasta, G.Maggiolo, S.Amadasi, F.Castelli, S. di Giambenedetto, D.Segala, P.Pierotti, P.Blanc, G.Lapadula, A.Sarracino, F.Zacchi, G.Carosi. Nei soggetti con confezione, HIV/HCV, mai esposti alla terapia anti HCV, l’incremento occasionale delle AST espone ad una più rapida progressione verso la cirrosi 12° congresso nazionale SIMIT (2013). HANDLE: 11392/2418007
32) M.Libanore, L.Sighinolfi, D.Segala, R.Bicocchi, M.Pantaleoni, S.Ceruti. Trombosi del seno sagittale superiore come manifestazione d’esordio d’infezione da HIV 12° congresso nazionale SIMIT (2013). HANDLE: 11392/2418002
33) Segala D, et al. Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 6° congresso Nazionale ICAR, comunicazione orale (2014). HANDLE: 11392/2347584
34) Strizzolo G, Segala D, Guardigni V, Sighinolfi L Depression and anxiety in HIV-onfected patients compared to HIV-negative subjects: an observational study at Ferrara hospital 6° Congresso nazionale ICAR (2014). HANDLE: 11392/2417998
35) L.E. Weimer…. D.Segala … G.Nardini Three-year follow up of Raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the NIA cohort. 6° congresso nazionale ICAR (2014). HANDLE: 11392/2417996
36) Libanore M., Bianco V, Pantaloni M, Segala D, Quarantotto F, Rossi M.R.,Zoppellari R. Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. XIII confesso Nazionale SIMIT (2014). HANDLE: 11392/2417993
37) A Orlandini, C Ferrari, G Taliani, E Biliotti, G Montalto, AR Capitano, A Giacometti, P Castelli, S Fargion, L Valenti, G Angarano, M Milella, S Madonia, B Stagno, M Andreoni, N Cesta, D Bartolozzi, E Salomoni, C Torti, V Pisani, A Gori, S Costarelli, J Vecchiet, K Falasca, M Libanore, D Segala, S Rosato, L Falzano, MG Quaranta and PITER Collaborating Group.
38) V Guardigni, D Segala, M Celico, MR Ambrosio, L Sighinolfi Endocrinological aspects of hypophosphatemia in HIV infection. Pilot study on Vitamin D supplementation: an observational study 7° congresso nazionale ICAR (2015). HANDLE: 11392/2417991
39) L Sighinolfi, G Ciancio, F Furini, D Segala, V Bagnari, I Farina, E Galuppi, M Libanore, M Govoni Entheseal involvement in asymptomatic HIV patients: an ultrasonographic study 7° congresso nazionale ICAR (2015)
40) V Guardigni, ML Morieri, D Segala, L Sighinolfi HIV clinical indicator diseases prior to HIV diagnosis are correlated to clinical progression in Late Presenters 7° congresso nazionale ICAR (2015). HANDLE: 11392/2417987
41) G Strizzolo, D Segala, G Fabbri, L Sighinolfi, M Libanore Quality of life in people living with HIV compared to HIV negative subjects: an observational study at Ferrara Hospital 7° congresso nazionale ICAR (2015). HANDLE: 11392/2417985
42) P. Nasta, A. Spinetti, L. Urbinati, P. Lanza, F. Maggiolo, E. Di Filippo, R. Gagliardini, D. Segala, P. Blanc, N. Ladisa, F. Zacchi, F. Castelli Genotype 3 HCV infection, lower CD4 cell count and higher liver stiffness are related with bone mineral reduction in HIV/HCV co- infected patients (MASTER cohort) 13TH EUROPEAN HIV & HEPATITIS MEETING (2015). HANDLE: 11392/2417885
43) Nasta P1 , Mengoli C, Spinetti A1, Pezzoli C 1,Brianese N1 F Maggiolo2 e E. Di Filippo2 , S. Digiambenedetto 3 , S. Costarelli 4 , A. Saracino 5 , B. Del Pin6 , D.Segala7 , F. Zacchi8, G. Carosi9 and the MaSTER study group. Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort)" 15th European AIDS Conference -EACS – (2015). HANDLE: 11392/2417875
44) Silvia Costarelli, Davide Bernasconi, Giuseppe Lapadula, Francesco Castelli ,Salvatore Casari , Franco Maggiolo, Antonella Grisolia, Annalisa Saracino, Gian Maria Baldin ,Massimo Dipietro , Daniela Segala, Chiara Fornabaio, Nicola Mazzini and Andrea Gori for the Italian MASTER cohort 15th European AIDS Conference -EACS – (2015). HANDLE: 11392/2417881
45) P. Nasta, C. Mengoli, A. Spinetti, F. Zacchi, F. Maggiolo, E. Di Filippo, N. Ladisa, A. Ferraresi, R. Gagliardini, D. Segala, P. Pierotti, S. Costarelli, F. Borghi, S. Amadasi, G. Carosi Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 13TH EUROPEAN HIV & HEPATITIS MEETING (2015). HANDLE: 11392/2417883
46) D Segala, G Fabbri, M Barotto, S Bianchi, L Sighinolfi The switch to generic antiretroviral drugs: safety, efficacy and patients’ feeling 7° congresso nazionale ICAR (2015). HANDLE: 11392/2417983
47) Segala D, Libanore M, Sighinolfi L. Efficacy and safety of switching from branded to generic efavirenz: one year Experience 8° congresso nazionale ICAR (2016). HANDLE: 11392/2417980
48) Alessandro Cozzi Lepri on behalf of PITER and ICONA/HepaICONA Studies Access to new generation DAA treatment in HIV-negative and HIV-positive individuals with F3-F4 stage of liver disease: results from PITER and Icona/HepaICONA cohorts 8° congresso nazionale ICAR (2016). hdl:11392/2417802. HANDLE: 11392/2417802
49) Barbara Coco on behalf of PITER and ICONA/HepaICONA Studies Clinical and virological characteristics of HIV and HCV coinfected versus HCV monoinfected patients: real life evaluation in PITER and ICONA/HepaICONA Italian cohorts 8° congresso nazionale ICAR (2016). HANDLE: 11392/2417810
50) L. Badia, R. Rossotti, S. Ianniruberto, T. Masi, V. Borghi, C. Puzzolante, G. Cuomo, D. Segala, M. Puoti, M. Galli, C. Uberti Foppa, P. Viale, G. Verucchi Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program Reviews in Antiviral Therapy & Infectious Diseases 2016, Abstract book of 12th International Workshop on Co-Infection HIV & Hepatitis. HANDLE: 11392/2418025
51) Segala D., CalacociI M., Tsucalas F., Libanore M., ContiniI C., Sighinolfi L. Intervento di formazione/informazione circa le modalità di trasmissione/prevenzione di malattie sessualmente trasmissibili (STDs) ad una popolazione di migranti richiedenti asilo/rifugiati con offerta attiva del test HIV. Studio pilota nella Provincia di Ferrara. Dati preliminari. XIV congresso nazionale SIMM (2016). HANDLE: 11392/2378903
52) Ciancio G, Sighinolfi L, Furini F, Segala D, Farina I, Galuppi E, De Stefani E, Simone L, Boccia S, Grilli A, Pazzi P, Libanore M, Contini C, Govoni M. Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study. EULAR (2016)
53) A Cozzi-Lepri, M Zaccarelli, S Rusconi, N Gianotti, S Bonora, A De Luca, G Madeddu, N Galizi, VEsposito, M Puoti, A d’Arminio Monforte and A Antinori for the Icona Foundation Study cohort. Two years of exposure to elvitegravir/cobicistat/emtricitabine/tenofovir(E/C/FTC/TDF): an overview of the trend in laboratory parameters in clinical practice. 16th European AIDS Conference (2017). HANDLE: 11392/2418120
54) A d'Arminio Monforte, A Antinori, A Cozzi-Lepri, F Ceccherini-Silberstein, E Girardi, A Castagna, S Lo Caputo, C Mussini, A De Luca, G Madeddu, A Cingolani, A Tavelli, G Taliani, A Gori, M Puoti and Icona Foundation Study Group. Predictors of access and response to DAA in a cohort of HIV/HCV co-infected patients in Italy. The International Liver Congress – EASL- (2017). DOI: 10.1016/s0168-8278(17)30893-0
55) Maritati Martina; Trentini Alessandro; Lo Menzo Sara; Segala Daniela; Contini Carlo; Sighinolfi, Laura Evaluation of the switch to a dual art regimen with lamivudine plus dolutegravir or protease inhibitors in hiv-infected virologically suppressed patients. a real life experience 9° Congresso nazionale ICAR (2017). HANDLE: 11392/2378844
56) Martina Maritati, Laura Sighinolfi, Daniela Segala, Lorenzo Massoli, Enrico Biagi, Mariachiara di nuzzo, Marco Libanore, Shawgi Almugadam, Carlo Contini Relapse of visceral and cutaneous leishmaniasis in a patient with advanced hiv infection despite liposomal amphotericin b therapy and prophylaxis. diagnostic and therapeutic issues. 6th World Congress on Leishmaniasis (2017)
57) Maritati Martina; Sighinolfi Laura; Di Nuzzo Mariachiara; Zanotta Nunzia; Segala Daniela; Comar, Manola; Contini Carlo Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 28th European Congress of Clinical Microbiology and Infectious Disease ECCMID (2018). HANDLE: 11392/2382936
58) Pierluca Piselli, Diego Serraino, Alessandra Bandera, Andrea Antinori, Enrico Girardi, Claudia Cimaglia, Alessandro Tavelli, Francesca Bai, Gianmaria Baldin, Andrea Calcagno, Antonella d'Arminio Monforte, Antonella Cingolani for the ICONA Foundation StudyGroup NON-AIDS RELATED CANCER RISK IS NOT AFFECTED BY cARTIN ICONA COHORT 10° Congresso nazionale ICAR (2018)
59) A Vergori, P Lorenzini, A Cozzi-Lepri, F Maggiolo, G Lapadula, A De Luca, A Cingolani, M Galli, G Mazzarello, P Milini, A d’Arminio Monforte, A Antinori on behalf of ICONA Foundation Study Group. Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort. HIV DRUG THERAPY (2018). HANDLE: 11392/2418116
60) E Girardi , A Cozzi-Lepri , A Gori , A Saracino , A Di Biagio , G Lapadula , G Orofino , M Lichtner , S Lo Caputo , A Antinori , A d'Arminio Monforte , C Mussini , for the Icona Foundation Study Group. HIV-associated TB in a low burden country: is screening for latent TB still needed? 25th CROI – Conference on Retrovirus and Opportunistic Infections. (2018). HANDLE: 11392/2418058
61) Di Nuzzo Mariachiara, Segala Daniela, Sighinolfi Laura. CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 11° Congresso nazionale ICAR (2019). HANDLE: 11392/2417786
62) R Gagliardini, P Lorenzini, A Cozzi-Lepri, N Gianotti, L Sarmati, S Rusconi, E Messina, A Capetti, A Saracino, G Madeddu, A d'Arminio Monforte, A Antinori, for the ICONA Foundation Study Group. Evolution and reversibility of renal function after switch from TDF to TAF regimens 26th CROI Conference on Retrovirus and Opportunistic Infections (2019). HANDLE: 11392/2418056
63) V Spagnuolo, L Galli, A Cozzi-Lepri, G Lapadula, A Antinori, G Orofino, N Bobbio, MC Moioli, A Calcagno, A De Luca, A d'Arminio Monforte, A Castagna, for the ICONA Foundation Study Group. Time to undetectable viral load achievement after art start and risk of mortality. 26th CROI Conference on Retrovirus and Opportunistic Infections (2019). HANDLE: 11392/2418054
64) A Mondi, P Lorenzini, A Tavelli, A Cozzi-Lepri, F Maggiolo, N Gianotti, D Francisci, C Carcieri, A De Vito, A Di Biagio, A d'Arminio Monforte, A Antinori, for the ICONA Foundation Study Group. Effectiveness of single- vs multiple-tablet regimens as 1st-line ART in ICONA Cohort. 26th CROI Conference on Retrovirus and Opportunistic Infections (2019). HANDLE: 11392/2418052
65) R. Rossotti, G. Guaraldi, A. Cozzi Lepri, V. Spagnuolo, S. Cicalini, J. Vecchiet, E. Quiros Roldan, G. Madeddu, S. Lo Caputo, A. Antinori, M. Puoti, A. d’Arminio Monforte on behalf of the ICONA Foundation Study Group. Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort. The 17th European AIDS Conference – EACS- (2019). HANDLE: 11392/2418044
66) A. Mondi, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, M. Puoti, V. Barocci, A. Londero, F. Bai, C. Pinnetti, P. Cinque, A. d’Arminio Monforte8, A. Antinori on behalf of the Icona Foundation Study Group. Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (art): data from icona foundation study cohort. The 17th European AIDS Conference - EACS- (2019). HANDLE: 11392/2418048
67) S. Leone, P. Lorenzini, A. Cozzi-Lepri, G. Orofino, D. Bernacchia, A. Castagna, M. Menozzi, G. Guaraldi, G. Madeddu, A. Di Biagio, A. Gori, A. d'Arminio Monforte, for the ICONA Foundation Cohort Study Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research (2019). HANDLE: 11392/2418112
68) D. Segala, A. Zannini, B. Cantarelli, A. Giannini, G. Mattei, R. Cultrera, L. Sighinolfi Counsellin and HIV Rapid Test for marginalized groups: data from an Emilia Romagna Region project 12° Congresso ICAR - Italian Conference on AIDS and Antiviral Research (2020). HANDLE:11392/2422610
69) E.S. Cannizzo1, A Cozzi-Lepri2, F. Ceccherini S.3, R. Scutari3, C. Alteri4, A. Tavelli5, D. Bernacchia6, E. Merlini1, A. Castagna7, A. Antinori8, A. d’Arminio Monforte1, G. Marchetti1 on behalf of Icona and TAF-Icona Study Groups Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART 12° Congresso ICAR - Italian Conference on AIDS and Antiviral Research (2020). HANDLE:11392/2422613
70) A.Tavelli, S.Cicalini, D.Barbanotti, S.Antinori, D.Segala, G.Guaraldi, M.Guastavigna, C.Lazzaretti, M.Puoti, F.Ceccherini-Silberstein, A.Castagna, E.Girardi, A.D'Arminio Monforte, A.Antinori,for the Icona Study Group Proportion of PLWH not vaccinated for Covid-19 in Italy and predictors CROI 2022. Conference on retroviruses and opportunistic infections (2022).
71) P Piselli, A De Vito, A Tavelli, C Cimaglia, A Nappo, M Farinella, L Rancilio, L Cosmaro, C Muccini, C Santoro, D Segala, M Trizzino, A Caraglia, A d’Arminio Monforte, A Antinori, E Girardi, G Madeddu, for ICONA Foundation Study Group and for the Working Group of the project “The impact of COVID-19 on the processes and outcomes of care of people with HIV” Impact of COVID-19 in time to linkage to care (LtC) and ART initiation in ICONA Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
72) R. Cultrera, M. Gatti, M. E. Michelini, A. Marra, D. Segala, B. Quarta, D. Persichetti, Proietti, S. Ambretti, C. Vella Efficacia di cefiderocol per il trattamento di infezione post-traumatica da stenotrophomonas maltophilia in un paziente di 12 mesi: determinazione della dose terapeutica XXII Congresso Nazionale SIMIT (Ottobre 2023)
73) R. Cultrera, A. Marra, M. Benazzi, M. Di Nuzzo, D. Segala, M. Libanore, A. Bonazza, B. Quarta Impego di dalbavancina nella terapia delle infezioni da gram-positivi nel paziente non ospedalizzato: Cinque anni di esperienza XXII Congresso Nazionale SIMIT (Ottobre 2023)
74) R. Luzzati, V. Zerbato, L. Attard, G. Virgili, A. Cilli, A. Zanier, M. Libanore, D. Segala, A. Tedesco, M. E. Bortolotti, E. Pontali, M. Feasi, M. Campanini, A. Re, E. Zagarrì, F. Dentali, D. Manfellotto, S. Di Bella, E. Concia Il Registro Italiano Fadoi-Simit delle febbri di origine sconosciuta XXII Congresso Nazionale SIMIT (Ottobre 2023)
75) B. Dallan, M. Campagnaro, E. Gallerani, D. Proietto, R. Cultrera, M. Libanore, L. Sighinolfi, S. Ghisellini, S. Llewellyn-Lacey, V. Appay, D. A. Price6,, F. Nicoli, A. Caputo, D. Segala Antiretroviral therapy restores naïve t cell frequencies oc 8 and functionality in PLWH 16° Congresso Nazionale ICAR.Roma, 19-21 Giugno 2024
76) A. d'Arminio Monforte, A. Rodano', I. Fanti, C.F. Perno, D. Segala, A. Santoro, M.B. Pasticci, L. Calza, A. Carraro, A. Cingolani, M. Puoti, A. Castagna, S. Lo Caputo, A. Tavelli, A. Antinori on behalf of Icona Foundation Study Group Socio-demographic, clinical and therapeutic features of persons with hiv (pwh) currently in care in italy: data from the icona cohort 16° Congresso Nazionale ICAR.Roma, 19-21 Giugno 2024
77) D. Segala, C. Bardellini, P. Mori, R. Cultrera New tools in the management of innovative HIV therapy. Pilot study 8th National Congress of the Italian Society for Virology. (Luglio 2024)
78) D. Segala, S. Altomari, R. Cultrera The impact of Highly Effective Antiretroviral Therapy on prevalence of AIDS and non-AIDS-defining cancers in people living with hiv attending the HIV/AIDS division of Ferrara Hospital 8th National Congress of the Italian Society for Virology (Luglio 2024)
|
